Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25213075 | 0.86 | HTR2A (0.37) | HTR2AHTR2CHTR2BGAA | |
| SCHEMBL15667176 | 0.79 | HTR2A (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL29661388 | 0.79 | HTR2A (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL24328553 | 0.79 | HTR2A (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL25713434 | 0.76 | ACHE (0.35) | — | |
| SCHEMBL23647902 | 0.71 | AHR (0.31) | — | |
| SCHEMBL23363798 | 0.71 | GAA (0.33) | GAA | |
| SCHEMBL8686728 | 0.71 | HTR4 (0.40) | — | |
| SCHEMBL25260111 | 0.71 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL31417658 | 0.69 | KDM4E (0.48) | HTR2AHTR2CHTR2BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| EP-3287463-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016169504-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | 广州再极医药科技有限公司 | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | PDK1, WEE1, DCK | HTR2A 4589/4885HTR2C 4241/4885HTR2B 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.